AOD-9604: The Fat Loss Fragment Peptide

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (HGH), specifically amino acids 176-191. It was engineered to retain HGH's fat-burning properties while eliminating effects on insulin sensitivity and IGF-1 production. Despite early promise in animal studies and initial human trials, AOD-9604 failed to receive FDA approval for obesity treatment in 2008, though it's still used off-label and sold as an oral supplement in Australia.

What Is AOD-9604?

AOD-9604 stands for "Anti-Obesity Drug" candidate 9604. It's not actually a drug anymore—at least not in the regulatory sense. The peptide consists of a 15-amino-acid sequence taken from the tail end of growth hormone, with a tyrosine added at the N-terminus to improve stability. Scientists at Monash University developed it in the late 1990s, hoping they'd found a way to tap into GH's lipolytic effects without triggering diabetes risk or acromegaly.

The theory was elegant. Since the 176-191 region of HGH appeared responsible for fat metabolism, isolating just that fragment might give you targeted fat loss. No more worrying about elevated blood sugar or thickened bones—just pure adipocyte mobilization.

Sounds too good to be true? Yeah, that's because it probably was.

The HGH Fragment: How AOD-9604 Was Derived

Human growth hormone is a 191-amino-acid protein. It does a lot: builds muscle, strengthens bones, regulates metabolism, influences sleep, affects insulin sensitivity. Back in the '80s and '90s, researchers noticed that fragmenting HGH could isolate specific functions. Some fragments promoted growth. Others seemed to preferentially target fat cells.

The C-terminal fragment—those last 15 amino acids—showed lipolytic activity in rodent studies. When you inject it into mice, they burn more fat. Their adipocytes release free fatty acids faster. Crucially, this happened without the growth-promoting or glucose-disrupting effects you'd see with full-length GH.

Metabolic Pharmaceuticals, an Australian biotech company, licensed the technology and modified the fragment slightly. They added that tyrosine residue to prevent rapid degradation and called their candidate AOD-9604. Clinical development began in the early 2000s.

The peptide was positioned as an anti-obesity therapeutic that could be injected subcutaneously, much like insulin. Early investors were optimistic. After all, obesity drugs were (and still are) a massive market opportunity.

Mechanism of Action: Lipolysis Without Growth Hormone Side Effects

AOD-9604 supposedly works by binding to the same receptors on fat cells that respond to growth hormone's lipolytic signal. When GH attaches to adipocytes, it activates hormone-sensitive lipase (HSL), the enzyme that breaks down stored triglycerides into free fatty acids and glycerol. Those fatty acids then enter circulation and get oxidized for energy.

The fragment peptide mimics that process—at least in theory. It binds, activates HSL, promotes lipolysis. But because it's missing the 1-175 portion of GH, it doesn't stimulate IGF-1 production in the liver. It doesn't mess with your glucose homeostasis or cause cartilage overgrowth.

Preclinical work suggested AOD-9604 might even have some anti-lipogenic properties, meaning it could reduce the formation of new fat in addition to breaking down existing stores. Some studies hinted at improved cartilage repair, though that wasn't the primary focus.

Does this mechanism hold up in humans? That's where things get murky. The FDA wasn't convinced the clinical data demonstrated meaningful efficacy, and neither were several independent reviews.

Clinical Trial History: From Promise to FDA Rejection

Metabolic Pharmaceuticals ran multiple Phase II trials in the early-to-mid 2000s. One of the larger studies enrolled over 300 obese participants and randomized them to receive either AOD-9604 injections or placebo for 12 weeks. Subjects were also put on a calorie-restricted diet and exercise program.

The results were... underwhelming. There was a modest trend toward greater fat loss in the AOD-9604 group compared to placebo, but the difference wasn't statistically significant in the primary endpoint. Some secondary analyses suggested benefits in specific subgroups, but that's classic post-hoc data mining—you torture the numbers long enough, they'll confess to anything.

In 2007, Metabolic Pharmaceuticals submitted a New Drug Application to the FDA. By 2008, the agency issued a Complete Response Letter, which is regulatory-speak for "not approved." The FDA cited insufficient evidence of efficacy and requested additional trials. The company didn't have the capital to fund more studies, so AOD-9604's future as a prescription obesity drug effectively ended.

It's a familiar story in peptide therapeutics. Animal models show promise, early human data looks interesting but inconclusive, and the bar for FDA approval is (appropriately) high. Many peptides get stuck in this limbo—too expensive to develop further, not quite compelling enough to attract big pharma partnerships.

Despite the regulatory failure, AOD-9604 didn't disappear. It migrated to the "research chemical" and "wellness peptide" markets, where it's sold for "research purposes only" or formulated into supplements.

AOD-9604 vs Semaglutide/Tirzepatide for Fat Loss

Let's be blunt: AOD-9604 isn't in the same universe as GLP-1 receptor agonists when it comes to evidence-backed weight loss. Semaglutide and tirzepatide have multiple large, well-controlled trials showing 10-20% body weight reductions over 68 weeks. AOD-9604 has one failed Phase II study and a bunch of anecdotal reports from peptide clinics.

Here's a comparison:

If you're looking for clinically validated weight management results, the GLP-1 drugs win by a landslide. But they're expensive, require prescriptions, and come with significant GI side effects that some people can't tolerate. AOD-9604 occupies a niche for those willing to experiment with less-proven options at a lower price point.

Is that rational? Debatable. But the market for peptides doesn't run purely on rationality—it runs on hope, optimization culture, and the appeal of "hacking" biology.

The Oral Supplement Form (TGA-Approved in Australia)

Here's where things get weird. In Australia, AOD-9604 is approved by the Therapeutic Goods Administration (TGA) as an oral supplement—not a drug—for weight management. It's sold under brand names like "AOD9604" by various supplement companies, often in sublingual or capsule form.

Oral bioavailability of peptides is notoriously poor. Your stomach acid and digestive enzymes tend to shred them before they reach circulation. That's why insulin is injected, not swallowed. For AOD-9604 to work orally, you'd need either extraordinary stability, a delivery system that protects it through the GI tract, or sublingual absorption that bypasses first-pass metabolism.

Some formulations claim to use proprietary encapsulation or absorption enhancers. Others are marketed as sublingual tablets meant to dissolve under the tongue. There's not much published data on the oral pharmacokinetics of AOD-9604, so it's hard to say whether these products deliver meaningful peptide levels to adipose tissue.

Australia's regulatory framework for supplements is less stringent than the FDA's drug approval process. The TGA listing doesn't require the same level of clinical proof that a pharmaceutical would. So while it's "legal" and "approved" in that context, it's not the same as FDA endorsement.

If you're considering oral AOD-9604, manage your expectations. The injectable form already has shaky efficacy data. An oral version faces even steeper pharmacological hurdles.

Dosing Protocols: Injection and Oral

Injectable AOD-9604: Most peptide clinics and research chemical suppliers recommend 300 mcg per day, administered subcutaneously in the morning on an empty stomach. Some protocols split the dose into 150 mcg twice daily. The idea is to time injections before periods of activity or fasting, when you'd theoretically want enhanced lipolysis.

Cycles typically run 8-12 weeks, though there's no standardized duration. Some users take it continuously; others cycle on and off. Since there's minimal data on long-term use, most conservative approaches treat it as a short-term intervention.

Reconstitution follows standard peptide protocols: you'll receive lyophilized powder, add bacteriostatic water, and store in the fridge. Injection sites rotate like any other subcutaneous peptide—abdomen, thighs, upper arms.

Oral AOD-9604: Oral supplement doses range from 1-2 mg per day, usually taken as sublingual tablets. The higher dose presumably compensates for poor absorption. You'd place the tablet under your tongue and let it dissolve, hoping some fraction enters your bloodstream directly through the mucosa.

Again, there's scant evidence on whether this actually works. If you're trying oral AOD-9604, you're essentially running an n=1 experiment.

For serious biohackers interested in tracking body composition changes, pairing any AOD-9604 protocol with diagnostic testing (DEXA scans, metabolic panels) makes sense. At least then you have objective data rather than guessing based on how your jeans fit.

Side Effects and Safety Data

One thing AOD-9604 has going for it: a relatively clean safety profile. In clinical trials, adverse events were minimal and similar to placebo. The most commonly reported issues were mild injection site reactions (redness, swelling) and occasional headaches. No serious adverse events were attributed to the peptide.

Because it doesn't elevate IGF-1 or interfere with glucose metabolism, you don't see the diabetic risk or cancer concerns that sometimes trail full-dose growth hormone use. It doesn't suppress natural GH production the way exogenous HGH might. And since it's not anabolic, there's no impact on hormone panels beyond the immediate lipolytic signal.

Long-term data is basically nonexistent, though. The longest controlled trial was 12 weeks. We don't know what happens if someone injects it daily for years. Could there be downstream metabolic adaptation? Receptor desensitization? Unknown antibody formation? Probably not anything dramatic, but "probably" isn't the same as "proven safe."

For context, even well-established therapies like GLP-1 agonists are still being studied for long-term cardiovascular and cancer outcomes. A peptide that never made it past Phase II doesn't have that luxury of post-market surveillance.

If you're considering AOD-9604, baseline health matters. Anyone with a history of cancer should be cautious with anything that touches growth pathways, even indirectly. People with metabolic disorders should monitor their response carefully. And obviously, pregnant or breastfeeding women should avoid experimental peptides altogether.

Why AOD-9604 Is Still Popular Despite Weak Evidence

So why do people still use it? A few reasons.

Cost. GLP-1 drugs can run $1,000-1,500 per month without insurance. AOD-9604 from research suppliers might cost $150-300 for a month's supply. For someone without insurance coverage or willing to bypass the prescription system, that's a massive difference.

Side effect profile. Semaglutide and tirzepatide work, but they make a lot of people feel awful. Nausea, vomiting, constipation, and the general malaise of chronic GI upset are common. AOD-9604 doesn't mess with your gut or appetite signaling, so it's theoretically "cleaner" even if less effective.

Stacking and optimization culture. Biohackers don't use peptides in isolation. They stack them with other compounds—maybe AOD-9604 for lipolysis, plus CJC-1295 for GH pulses, plus metformin for insulin sensitivity, plus a GLP-1 analog at a low dose. The idea is synergistic effects, though the evidence for these combinations is purely anecdotal.

Regulatory arbitrage. In the U.S., AOD-9604 exists in a legal gray zone. It's not FDA-approved, but it's not explicitly scheduled or banned either. Research chemical vendors sell it "for research purposes only," and peptide clinics prescribe it off-label. Some people prefer operating in that space rather than navigating traditional healthcare gatekeeping.

Hope. This might be the biggest factor. When you're struggling with body composition, you want solutions. AOD-9604 has a compelling origin story (derived from GH!), a plausible mechanism (targeted lipolysis!), and enough anecdotal reports to keep the dream alive. Even weak evidence can sustain a market if the alternative is giving up.

Does that make it a good choice? Not necessarily. But it explains why it's still around 15+ years after its FDA rejection.

Frequently Asked Questions

What is AOD-9604 used for?

AOD-9604 is used primarily for fat loss and body recomposition. It's marketed as a peptide that promotes lipolysis (fat breakdown) without affecting blood sugar, insulin sensitivity, or IGF-1 levels. Some users also report improvements in recovery and joint health, though those effects are less documented.

Is AOD-9604 FDA-approved?

No. AOD-9604 failed to gain FDA approval in 2008 after clinical trials didn't demonstrate sufficient efficacy for obesity treatment. It's not approved as a drug in the U.S., though it's sold as a research chemical or prescribed off-label by some peptide clinics. In Australia, it's approved as an oral supplement by the TGA.

How much weight can you lose with AOD-9604?

Clinical trial data showed minimal weight loss—around 2-3% of body weight over 12 weeks, and even that wasn't statistically significant compared to placebo. Anecdotal reports vary widely, with some users claiming 5-10 pounds of fat loss over 8-12 weeks when combined with diet and exercise. Results are highly individual and not well-validated.

What's the difference between AOD-9604 and HGH?

AOD-9604 is a 15-amino-acid fragment of human growth hormone, specifically the C-terminal region (amino acids 176-191). It's designed to mimic HGH's fat-burning effects without the growth-promoting, glucose-disrupting, or IGF-1-elevating properties of full-length GH. Think of it as a targeted snippet rather than the whole molecule.

Can you take AOD-9604 orally?

Yes, oral formulations exist, especially in Australia where it's sold as a TGA-approved supplement. However, peptides generally have poor oral bioavailability due to degradation in the digestive system. Sublingual tablets are meant to improve absorption, but there's limited data proving oral AOD-9604 reaches effective concentrations in the bloodstream.

What is the recommended AOD-9604 dosage?

For injectable AOD-9604, the typical dose is 300 mcg per day, administered subcutaneously in the morning on an empty stomach. Some protocols use 150 mcg twice daily. Oral supplements usually recommend 1-2 mg per day as sublingual tablets. Cycles commonly run 8-12 weeks.

Does AOD-9604 have side effects?

Side effects are minimal in reported trials. The most common issues are mild injection site reactions (redness, swelling) and occasional headaches. AOD-9604 doesn't affect insulin or IGF-1, so it doesn't carry the metabolic risks associated with full-dose growth hormone. Long-term safety data is lacking.

Can AOD-9604 build muscle?

No. AOD-9604 isn't anabolic. It doesn't stimulate muscle protein synthesis or IGF-1 production the way full-length growth hormone does. Its mechanism is purely lipolytic—breaking down fat. If you're looking for muscle growth, you'd want performance peptides like CJC-1295/Ipamorelin or traditional anabolics.

Is AOD-9604 better than semaglutide for fat loss?

No. Semaglutide has robust clinical trial data showing 15%+ body weight loss over 68 weeks. AOD-9604 failed to demonstrate significant efficacy in its Phase II trial. Semaglutide is FDA-approved; AOD-9604 isn't. However, AOD-9604 is cheaper and has fewer GI side effects, which appeals to some users willing to trade evidence for tolerability.

Where can you buy AOD-9604?

In the U.S., AOD-9604 is available from research chemical suppliers (sold "for research purposes only") and some peptide clinics that prescribe it off-label. In Australia, it's sold as an oral supplement by TGA-approved vendors. Quality and purity vary significantly between suppliers, so third-party testing (if available) is recommended.

How long does AOD-9604 take to work?

Anecdotal reports suggest users notice changes in body composition within 3-4 weeks, assuming consistent dosing and a calorie deficit. Clinical trials ran 12 weeks. Because individual response varies and the evidence base is weak, it's hard to pin down a reliable timeline. Some people report no effect at all.

Can AOD-9604 help with joint repair?

Some preclinical studies suggested AOD-9604 might support cartilage regeneration, and anecdotal reports mention improved joint comfort. However, this wasn't the primary focus of clinical development, and there's no strong human data. If joint health is your goal, peptides like BPC-157 or TB-500 have more relevant (though still largely anecdotal) support.

Is AOD-9604 safe for long-term use?

Unknown. The longest controlled trial was 12 weeks, and there's no post-market surveillance data. Short-term use appears safe based on trial reports, but multi-year safety hasn't been studied. Most conservative protocols treat AOD-9604 as a short-term (8-12 week) intervention rather than a continuous therapy.

Does AOD-9604 affect hormones?

No significant hormonal disruption has been reported. Unlike full-length HGH, AOD-9604 doesn't elevate IGF-1, suppress natural GH production, or interfere with thyroid or sex hormones. It's metabolically "quiet" beyond its intended lipolytic effect, which is part of its appeal compared to more systemically active compounds.

Final Thoughts

AOD-9604 represents a recurring theme in peptide therapeutics: elegant theory, underwhelming execution. On paper, isolating the fat-burning fragment of growth hormone makes perfect sense. In practice, a failed FDA trial and minimal robust evidence leave it in the realm of speculative biohacking rather than proven medicine.

That doesn't mean it's useless. Some people respond to therapies that don't work on average. Individual variation in receptor density, metabolic state, and lifestyle factors can make a marginal intervention meaningful for specific users. But banking on AOD-9604 as your primary fat-loss strategy—especially when alternatives like GLP-1 agonists exist—seems optimistic at best.

If you're exploring longevity and metabolic optimization, AOD-9604 might fit into a broader experimental protocol. Just go in with eyes open: you're not using an FDA-approved drug with decades of safety data. You're using a research peptide with one failed trial, anecdotal support, and a lot of unanswered questions.

Sometimes that's enough. Sometimes it isn't. The honest answer is we don't know—and the people selling it to you don't, either.